A study of cabozantinib vs. placebo in subjects with a form of liver cancer who have previously received sorafenib

Mise à jour : Il y a 5 ans
Référence : EUCTR2013-001001-91

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The objective of this study is to evaluate the effect of cabozantinib compared with placebo on overall survival in subjects with advanced HCC previously treated with sorafenib.


Critère d'inclusion

  • Subjects with Hepatocellular Carcinoma